Fluvoxamine
فلووکسامین
🧠 Nervous SystemSSRI
Market / country: 🇺🇸 USA
Luvox (US)
🧮 Dose calculator
Obsessive-compulsive disorder · Regimen source: FDA Fluvoxamine · 2.1FDA Fluvoxamine · 2
- • Increase by 50 mg every 4–7 days; max 300 mg/day; divide doses above 100 mg. FDA Fluvoxamine · 2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ With or within 14 days of an MAOI (including linezolid or IV methylene blue). FDA Fluvoxamine · 4
- ⛔ With tizanidine, thioridazine, alosetron or pimozide. FDA Fluvoxamine · 4
- ⛔ Not approved under 8 years (OCD only, 8–17 y). FDA Fluvoxamine · Boxed WarningFDA Fluvoxamine · 2.2
- ⚠️ Boxed warning: increased suicidal thoughts and behaviour in children, adolescents and young adults. FDA Fluvoxamine · Boxed Warning
Formulations
- 25 mg tablet — tablet 🇺🇸 USA FDA Fluvoxamine · 3
- 50 mg tablet (scored) — tablet 🇺🇸 USA FDA Fluvoxamine · 3
- 100 mg tablet (scored) — tablet 🇺🇸 USA FDA Fluvoxamine · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Fluvoxamine · 8.1
“Risk Summary Based on data from published observational studies, exposure to SSRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage [see Warnings and Precautions ( 5.10 ) and Clinical Considerations].”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Fluvoxamine · 8.2
“Data from published literature report the presence of fluvoxamine is in human milk (see Data).”
- 👶 ChildrenDangerous / avoid
Boxed warning in the label about children. FDA Fluvoxamine · Boxed Warning
“Fluvoxamine maleate tablets are not approved for use in pediatric patients except for patients with obsessive compulsive disorder (OCD) [see Warnings and Precautions ( 5.1 )] .”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Fluvoxamine · 8.5
“… ly significant hyponatremia in elderly patients, who may be at greater risk for this adverse event [see Warnings and Precautions ( 5.13 )] .”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Fluvoxamine · 8.3
“Infertility Animal findings suggest fertility may be impaired while taking fluvoxamine [see Nonclinical Toxicology ( 13.1 )].”
🔗 Reference links
- FDA (approval record)ANDA075902
- DailyMed (FDA label)FDA Fluvoxamine
- MedlinePlus (NIH)Fluvoxamine
- WHO ATC/DDDN06AB08
- Darooyab (Iran)Fluvoxamine
🇮🇷 Registered in Iran Darooyab · G-586/Fluvoxamine
Dosage forms with Iranian generic codes, per Darooyab.
- 04708 · FLUVOXAMINE MALEATE 100MG TAB · قرص فلووکسامین مالئات ۱۰۰ میلیگرم
- 01827 · FLUVOXAMINE MALEATE 50MG TAB · قرص فلووکسامین مالئات ۵۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Fluvoxamine · 3FDA Fluvoxamine · 2.1FDA Fluvoxamine · 2FDA Fluvoxamine · 2.2FDA Fluvoxamine · 4FDA Fluvoxamine · Boxed WarningFDA Fluvoxamine · 8.1FDA Fluvoxamine · 8.2FDA Fluvoxamine · 8.5FDA Fluvoxamine · 8.3FDA Fluvoxamine · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-586/Fluvoxamine
- Clinical review⚠ Unverified